Overview

Avapritinib Rollover Study

Status:
RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Phase:

PHASE4

Details

Lead Sponsor:

Blueprint Medicines Corporation

Treatments:

avapritinib